Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Net Receivables · Q4 FY2025 · quarter ended Dec 2025
Net receivables rises 243.4% from a year ago
Net receivables stood at $3.66M at the end of Q4 FY2025, up 243.4% from a year earlier. Over 3 fiscal years it compounded at +907.0% a year.
Context
- Net receivables amounted to 12.1% of total assets at the end of Q4 FY2025, up 6.5 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +243.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 3.66M USD
- Year-over-year change
- +243.4%
- 4-year CAGR
- +50.3%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.66M | +243.4% |
| FY2024 | 2024-12-31 | 1.06M | -43.5% |
| FY2023 | 2023-12-31 | 1.88M | +52537.8% |
| FY2022 | 2022-12-31 | 3.58K | -99.5% |
| FY2021 | 2021-12-31 | 717.5K | — |
Net Receivables vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +243.4% is the highest of 10, against a peer median of +7.2%.
- Net receivables amounts to 12.1% of total assets for NNNN, versus a peer median of 9.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.37B USD | -4.4% | +1.9% | 17.9% | |
| Mar 2026 | $103M USD | -1.7% | -14.8% | 9.8% | |
| Mar 2026 | $49.95M USD | +20.2% | +8.7% | 9.9% | |
| Feb 2026 | $45.55M USD | -7.0% | -8.6% | 17.5% | |
| Mar 2026 | CA$31.91M CAD | +7.2% | +10.4% | 2.4% | |
| Mar 2026 | $23.59M USD | +78.1% | +18.5% | 17.3% | |
| Mar 2026 | $15.13M USD | -51.7% | -0.5% | 2.8% | |
| Dec 2025 | $11.3M USD | — | — | 3.4% | |
| Mar 2026 | $9.35M USD | +42.1% | — | 7.3% | |
| Mar 2026 | $8.66M USD | +137.3% | +39.7% | 9.3% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $3.66M USD | +243.4% | +907.0% | 12.1% |
| Peer median (excluding NNNN) | — | +7.2% | +5.3% | 9.5% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.